CXCL10 and asthma: Combined treatment of ICS with a β2AR agonist reduced RV-induced epithelial production of the chemokines CCL5, CXCL8, and IP-10, VEGF, and FGF2 in vitro [168, 169], highlighting the success of combination therapy in managing asthma exacerbations and airway remodeling lesions.